Blog
The case for patient-controlled rare disease data across science, policy, and the lived experience.
Featured
Patient Experience
What the system tells us
Nine sentences inherited from a different era.
Read →This week
Search articles
Browse by tag
Clear ×Read all29 of 117 · Tag: Accelerating innovation
- May 7, 2026The speed thesis
- May 7, 2026The community review as clinical trial
- May 7, 2026The cure horizon
- May 7, 2026The acceleration equation
- May 7, 2026The rare disease data market
- May 7, 2026The provider discovery problem
- May 7, 2026The global natural history study
- May 7, 2026High consanguinity as research accelerator
- May 7, 2026The regulatory arbitrage opportunity
- May 7, 2026Rare disease as the proving ground
- May 7, 2026The real-time trial as default
- May 7, 2026The product review as outcomes data
- May 7, 2026The insurance argument that wins
- May 7, 2026The end of the diagnostic odyssey
- May 7, 2026The phenotype cloud
- May 7, 2026The incidental diagnosis cascade
- May 7, 2026Control data for the next cure
- May 7, 2026Cross-condition signal detection
- May 7, 2026From Orphan Drug to Platform Drug
- May 7, 2026How Data Cures Rare Disease
- May 7, 2026The Drug Made for One
- May 7, 2026What the Nurses' Health Study Built, and What Rare Disease Lacks
- May 7, 2026Sponsors Leave. Patients Don't.
- May 7, 2026The Economics of One
- May 7, 2026The N-of-1 Trial as Infrastructure
- May 7, 2026The Parent Scientist
- May 7, 2026The Time Value of Data
- May 7, 2026When Diagnostic Categories Dissolve
- May 7, 2026Why We Say Cure